MedPath

Benefits of a Bolus Calculator in Pediatric Patients on Multiple Daily Insulin Injections

Not Applicable
Completed
Conditions
Poor Glycemic Control
Quality of Life
Interventions
Device: accu chek Aviva Expert
Device: Accu Chek Aviva Nano
Registration Number
NCT06141629
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Brief Summary

It it hypothesized that children and adolescents with type 1 diabetes, who are counting carbohydrates can achieve better metabolic control by concurrent use of the Accu-Chek Aviva Expert. Additionally, it is proposed that carbohydrate counting in combination with the the Accu-Chek Aviva Expert will lead to better quality of life as a result of fewer restrictions when eating and less variation in blood glucose.

Detailed Description

Carbohydrate (Carb) counting is a meal planning approach for patients with diabetes mellitus that focuses on carbohydrate as the primary nutrient affecting postprandial glycaemic response. In the early 1990's the Diabetes Control and Complications Trial (DCCT) used Carb counting as one of its education tools. More recently, short acting insulin analogues and insulin pumps have made the role of Carb counting important and popular. Carb counting can be used to estimate carbohydrate intake and adjust insulin around mixed meals and snacks using insulin to carbohydrate ratio. This effectively addresses the variable eating habits of most children and adolescents. Carb counting can make food planning more flexible and thus more acceptable for young patients with diabetes.

Roche has recently launched the Accu-Chek Aviva Expert recently preliminary tested in adults4, being a blood glucose meter with integrated bolus calculator and memory function. This bolus calculator estimates the dose of insulin to be administrated on the basis of the following parameters: Current blood glucose, grams of carbohydrate, carbohydrate to insulin ratio, insulin sensitivity, target blood glucose and insulin action time.

Hypothesis:

It is hypothesized that paediatric patients in MDI therapy with suboptimal regulated diabetes will achieve better glycemic control by using Accu-Chek Aviva Expert rather than carbohydrate counting alone without the use of an external calculator.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
    • Patients with type 1 diabetes (n=120) Age > 1 year and < 18 years
  • Diabetes duration >12 months
  • MDI therapy (fast acting analog for meals; long acting analog as basal)
  • HbA1c > 7.0% and <11%
Exclusion Criteria
  • Insulin pump therapy
  • Missing consent declaration

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Accu check NanoAccu Chek Aviva NanoAccu check Nano
Accu-Chek Aviva Expert.Accu Chek Aviva NanoAccu-Chek Aviva Expert. This is a glucometer with boluscalculator.
Accu check Nanoaccu chek Aviva ExpertAccu check Nano
Accu-Chek Aviva Expert.accu chek Aviva ExpertAccu-Chek Aviva Expert. This is a glucometer with boluscalculator.
Primary Outcome Measures
NameTimeMethod
better metabolic control as assessed by HbA1C12 months

We hypothesize that children and adolescents with type 1 diabetes, who are counting carbohydrates can achieve better metabolic control as assessed by HbA1C.

Secondary Outcome Measures
NameTimeMethod
better quality of life as assessed by Hvidore questionnaire12 months

quality of life as assessed by Hvidore questionnaire

better metabolic control as assessed by glucose variability12 months

We hypothesize that children and adolescents with type 1 diabetes, who are counting carbohydrates can achieve better metabolic control as assessed by glucose variability by concurrent use of the Accu-Chek Aviva Expert. Additionally, we propose that carbohydrate counting in combination with the the Accu-Chek Aviva Expert will lead to better quality of life as a result of fewer restrictions when eating and less variation in blood glucose.

Trial Locations

Locations (1)

UZLeuven

🇧🇪

Leuven, Belgium

© Copyright 2025. All Rights Reserved by MedPath